News

June 01 2023:   

We are excited to announce that we have received funding from the North Carolina Biotechnology Center (NCBiotech)! This funding will support our efforts to bring our innovative nanovisQ technology to market.

In  addition to the financial support, we are excited about the access to  NC Biotech's expertise and network of contacts. This will be invaluable  as we work to grow our business and make a positive impact on the world.

We are grateful for the support of NCBiotech and we look forward to working with them to make our vision a reality.

December 01 2022:   

QATCH Technologies attended the “2022 MRS Fall Meeting & Exhibit” in Boston this week and our founder and CEO, Zehra Parlak, made a presentation about our nanovisQ technology in the “iMatSci  Innovator Speed Pitches & Q&A” section. Thank you for all  investors and companies for learning about our nanovisQ technology and  meeting with us there!

February 01 2022:   

QATCH Technologies is pleased to announce that  it has been awarded $1.5M SBIR Phase II grant from NIH to help further  development and commercialization of the nanovisQ™ technology. This  grant is a continuation of the SBIR Phase I received in 2020 and it will  help us to focus on manufacturing scale-up of the nanovisQ™.  
 

The  nanovisQ™ can measure viscosity of biopharmaceutical formulations by  using a small drop and then determine injectability of these  formulations. The rapid and extremely low sample volume measurements of  the nanovisQ™ enables early stage injectability screening.

September 08 2020:   

QATCH Technologies is proud to announce two new SBIR grants to further development of the nanovisQ™. QATCH’s nanovisQ™ technology is designed to de-risk injectable therapeutics development by providing an early stage injectability screening tool for biopharma R&D.

The National Science Foundation (NSF) has awarded QATCH an SBIR Phase I grant. This SBIR Phase I grant will help us investigate multiplexing our unique nanovisQ™ technology to achieve a high-throughput biopharmaceutical formulation testing.

The National Institute of Standards and Technology (NIST) has awarded QATCH an SBIR Phase II grant. This grant builds on the successfully completed Phase I. It will fund our research towards the scaled-up manufacturing and long-term deployability of our sensors.  

August 01 2020: QATCH is awarded an SBIR grant by National Institute of General Medical Sciences (NIGMS) of National Institute of Health (NIH). This funding will help QATCH to extend the measurement range of it's nanovisQ technology. The nanovisQ had already demonstrated extremely low volume and rapid viscosity measurement on biopharmaceutical formulations. 

August 01 2019: QATCH is awarded a Small Business Innovation and Research grant by National Institute of Standards and Technology to investigate  injectability and manufacturability screening for biopharmaceutical formulations by QATCH's unique viscosity sensors.  

May 16 2019: The annual meeting of The Society of Rheology draws physicists and engineers

from across the world every year to present work with a focus on rheology and condensed matter

physics, resulting in a vibrant meeting with extensive opportunities to learn and establish new

relationships. Dr. Parlak is invited as Keynote speaker for Rheometry: Advanced Techniques and Methods session to present in October 2019. More info: https://www.rheology.org/sor/Annual_Meeting/2019Oct/Default

April 01 2018: Dr. Dwight Walker, who is a Duke alumni, joined QATCH Technologies as Chief Operating Officer. Dr. Walker has extensive experience in developing instruments for pharmaceutical industry. 

October 30 2017: QATCH facilities moved to historic Chesterfield building in Downtown Durham. 

June 30 2017: QATCH Technologies is awarded a Small Business Technology Transfer (STTR) Phase I award by NSF and NC Matching award to investigate and commercialize it's proprietary low volume viscosity monitoring technology for point of care diagnosis.